{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee M"],"funding":["Stand Up To Cancer","NIDCR NIH HHS","Jayme and Peter Flowers Fund","NIH Cancer Center Support Grant","PaineWebber Chair","STARR Cancer Consortium","Sebastian Nativo Fund","NCI NIH HHS","Fundación Alfonso Martín Escudero","NIH","Pershing Square Sohn Cancer Research Foundation"],"pagination":["45-55"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8738128"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["20(1)"],"pubmed_abstract":["Targeted inhibition of BRAF V600E achieves tumor control in a subset of advanced thyroid tumors. Nearly all tumors develop resistance, and some have been observed to subsequently undergo dedifferentiation. The molecular alterations associated with thyroid cancer dedifferentiation in the setting of BRAF inhibition are unknown. We analyzed targeted next-generation sequencing data from 639 advanced, recurrent and/or metastatic thyroid carcinomas, including 15 tumors that were treated with BRAF inhibitor drugs and had tissue sampled during or posttreatment, 8 of which had matched pretherapy samples. Pre- and posttherapy tissues from one additional patient were profiled with whole-exome sequencing and RNA expression profiling. Mutations in genes comprising the SWI/SNF chromatin remodeling compl"],"journal":["Molecular cancer research : MCR"],"pubmed_title":["Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy."],"pmcid":["PMC8738128"],"funding_grant_id":["R01 DE027738","R35 CA232097","R01 CA205426","R01 CA255211","P30 CA008748","R01 CA173592","K08 DE024774","R01 CA050706"],"pubmed_authors":["Wong RJ","Morris LGT","Lee M","Makarov V","Fagin JA","Nadeem Z","Ho AL","Sherman EJ","Patel N","Valero C","Untch BR","Xu B","Ghossein R","Dogan S","Chan TA","Han C","Kuo F"],"additional_accession":[]},"is_claimable":false,"name":"Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy.","description":"Targeted inhibition of BRAF V600E achieves tumor control in a subset of advanced thyroid tumors. Nearly all tumors develop resistance, and some have been observed to subsequently undergo dedifferentiation. The molecular alterations associated with thyroid cancer dedifferentiation in the setting of BRAF inhibition are unknown. We analyzed targeted next-generation sequencing data from 639 advanced, recurrent and/or metastatic thyroid carcinomas, including 15 tumors that were treated with BRAF inhibitor drugs and had tissue sampled during or posttreatment, 8 of which had matched pretherapy samples. Pre- and posttherapy tissues from one additional patient were profiled with whole-exome sequencing and RNA expression profiling. Mutations in genes comprising the SWI/SNF chromatin remodeling compl","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-03-16T15:49:44.415Z","creation":"2022-07-10T09:34:41.864Z"},"accession":"S-EPMC8738128","cross_references":{"pubmed":["34635506"],"doi":["10.1158/1541-7786.mcr-21-0442","10.1158/1541-7786.MCR-21-0442"]}}